An Open-Label, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACC-1898 (Tyrosine Kinase Inhibitor) in Adult Participants With Advanced Solid Tumors.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07252661

Title field or adapter rule

{'original_value': 'An Open-Label, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACC-1898 (Tyrosine Kinase Inhibitor) in Adult Participants With Advanced Solid Tumors.', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:29.719689+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Source Retrieved At

2026-10-31T22:18:28.651351+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Hepatocellular Carcinoma", "Renal Cell Carcinoma", "Thyroid Carcinoma, Medullary", "Thyroid Carcinoma Primary Differentiated", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Melanoma", "Gall Bladder Cancer", "Advanced Solid Tumor"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT07252661"

protocolSection.identificationModule.officialTitle

"An Open-Label, Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of ACC-1898 (Tyrosine Kinase Inhibitor) in Adult Participants With Advanced Solid Tumors."

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
• Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Thyroid Carcinoma, Medullary (protocolSection.conditionsModule.conditions)
• Thyroid Carcinoma Primary Differentiated (protocolSection.conditionsModule.conditions)
• Gastric Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Gastroesophageal Junction Adenocarcinoma (protocolSection.conditionsModule.conditions)
• Melanoma (protocolSection.conditionsModule.conditions)
• Gall Bladder Cancer (protocolSection.conditionsModule.conditions)
• Advanced Solid Tumor (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['ACC-1898 Dose Expansion Cohorts', 'Participants receive ACC-1898 tablets orally once daily (QD) in 21-day cycles'], 'description': 'ACC-1898 is an oral small-molecule tyrosine kinase inhibitor (TKI).\n\nAdministered once daily by mouth in continuous 21-day cycles.\n\nStarting doses range from 80 mg to 300 mg QD, with possible intra-patient dose modifications.\n\nArm(s)/Group(s):\n\n* Arm 1 - ACC-1898 Monotherapy\n* Arm 2 - ACC-1898 Monotherapy\n\nRoute of Administration:\n\nOral (tablet)\n\nDose Form:\n\nFilm-coated tablet (20 mg and 40 mg strengths)\n\nTreatment Duration:\n\nUp to 2 years or until disease progression or unacceptable toxicity.', 'name': 'ACC-1898', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• ACC-1898 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.